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ABSTRACT Clinical data on primary ciliary dyskinesia (PCD) are limited, heterogeneous and mostly
derived from retrospective chart reviews, leading to missing data and unreliable symptoms and results of
physical examinations. We need standardised prospective data collection to study phenotypes, severity and
prognosis and improve standards of care.
A large, international and multidisciplinary group of PCD experts developed FOLLOW-PCD, a standardised
clinical PCD form and patient questionnaire. We identified existing forms for clinical data collection via the
Better Experimental Approaches to Treat PCD (BEAT-PCD) COST Action network and a literature review.
We selected and revised the content items with the working group and patient representatives. We then revised
several drafts in an adapted Delphi process, refining the content and structure.
FOLLOW-PCD has a modular structure, to allow flexible use based on local practice and research focus.
It includes patient-completed versions for the modules on symptoms and lifestyle. The form allows a
comprehensive standardised clinical assessment at baseline and for annual reviews and a short
documentation for routine follow-up. It can either be completed using printable paper forms or using an
online REDCap database.
Data collected in FOLLOW-PCD version 1.0 is available in real-time for national and international
monitoring and research. The form will be adapted in the future after extensive piloting in different
settings and we encourage the translation of the patient questionnaires to multiple languages. FOLLOW-
PCD will facilitate quality research based on prospective standardised data from routine care, which can be
pooled between centres, to provide first-line and real-time evidence for clinical decision-making.
@ERSpublications
Standardised follow-up of PCD patients enables quality research with real-time data from
routine care, providing evidence for clinical decision-making http://bit.ly/2PDfISF
Cite this article as: Goutaki M, Papon J-F, Boon M, et al. Standardised clinical data from patients
with primary ciliary dyskinesia: FOLLOW-PCD. ERJ Open Res 2020; 6: 00237-2019 [https://doi.org/
10.1183/23120541.00237-2019].
Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution
Non-Commercial Licence 4.0.
This article has supplementary material available from openres.ersjournals.com
Received: 6 Sept 2019 | Accepted after revision: 12 Dec 2019
https://doi.org/10.1183/23120541.00237-2019 ERJ Open Res 2020; 6: 00237-2019
ORIGINAL ARTICLE
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Introduction
Primary ciliary dyskinesia (PCD) is a rare, genetic, multi-organ disease characterised by dysfunction of
motile cilia [1]. A European Respiratory Society taskforce performed a survey in 26 European countries in
2007–2009 and found that care of children with PCD was heterogeneous and decentralised [2, 3].
Although some countries have established designated PCD centres in the meantime, the situation has not
changed substantially [4, 5]. Management recommendations are based on expert opinion and observations
from few patients, or are extrapolated from other chronic respiratory diseases such as cystic fibrosis (CF)
and non-CF bronchiectasis [6, 7]. We need better evidence on PCD clinical phenotypes, severity and
prognosis and on the factors that influence these to improve the standards of care and tailor care to
patient needs.
Availability of clinical data for PCD research is limited. There are few patient registries and these collect
limited phenotypic data [5, 8]. Conversely, detailed data are regularly collected in clinics during care of
PCD patients, but not in a standardised way [9, 10]. Retrospective data collection from charts leads to
heterogeneous clinical data with many missing items; it is unreliable for symptoms and results of physical
examination [11, 12]. Every clinic collects information in a different way, and even within clinics,
recording of patient history and clinical examination varies between physicians and clinical specialties. In a
systematic review of all publications describing clinical manifestations in PCD, we found that symptoms
had been assessed in such a heterogeneous way that pooling of data or comparisons between studies was
impossible [10]. This highlights the need for standardised collection of clinical data to be used in
well-designed real-time clinical research.
To address these issues, we developed FOLLOW-PCD, a disease-specific form for standardised prospective
data collection during routine clinical follow-up of PCD patients.
Methods
The protocol for the development of FOLLOW-PCD consisted of several steps (figure 1). This article
describes in detail the first steps of the protocol and the resulting version 1.0 of FOLLOW-UP in English.
In addition, it explains the next planned steps.
Working group
FOLLOW-PCD was developed by a multidisciplinary, international working group of the BEAT-PCD
(Better Experimental Approaches to Treat PCD) COST Action network (www.beatpcd.org/) [13–15].
BEAT-PCD is a European-led network of >250 scientists and clinicians from 25 countries, coordinating
research to improve the care and diagnosis of PCD. The FOLLOW-PCD working group consisted of 41
members of the BEAT-PCD network from 12 countries, mainly Europe. The composition of the group
reflected the BEAT-PCD network: 24 paediatric respiratory physicians, three adult pulmonologists, one
otolaryngologist, four diagnostic experts, two clinical nurse specialists, three physiotherapists and four
epidemiologists (supplementary table S1). 26 clinical centres, with >1000 PCD patients under care in total,
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were represented in the working group by one or more team members. The project was developed and
coordinated by the two co-principal investigators (MG and CK) from the Institute of Social and Preventive
Medicine (ISPM; Bern, Switzerland).
Identification and selection of content items
We contacted all members of the BEAT-PCD network to identify any forms that were already in use for
data collection during clinical follow-up visits. We asked about PCD-specific forms and forms used for
patients with other chronic respiratory diseases, e.g. CF and non-CF bronchiectasis. In addition, we
performed a systematic literature search to find clinical studies of PCD patients that used a standardised
clinical assessment form. We searched for studies published between January 1980 and April 2016
including published abstracts, without restrictions in language or study design.
Only eight centres, from five countries, out of the 22 countries participating in BEAT-PCD, used
PCD-specific forms for the follow-up of patients. The literature search did not yield additional forms. We
compared content and structure of the forms. These assessed roughly the same information, but not in a
standardised way. The item categories contained in most forms were 1) summary of diagnostic
information; 2) short clinical history; 3) summary of physical examination of the lungs; 4) lung function
measurement; 5) results of microbiology testing; 6) results of imaging; and 7) recommended medication.
Information on the upper airways, fertility and patient-reported outcomes were almost never included.
At the inaugural BEAT-PCD meeting in Southampton, UK (December 2015), participants exchanged ideas
and opinions about content and format of the standardised follow-up form (figure 1) [13]. We agreed on
the need for an extensive baseline form and a short form for regular follow-up. The advantages and
disadvantages of different versions for paediatric and adult patients were discussed.
We then discussed the content items identified in face-to-face meetings and group telephone conferences
with the working group and with patient representatives. This enabled the identification of additional
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FIGURE 1 Development process of the standardised pulmonary ciliary dyskinesia (PCD) follow-up form
(FOLLOW-PCD).
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items. Patient representatives provided specific feedback, particularly on the need to include
patient-reported symptoms.
Drafting and refining the standardised follow-up form
Based on the final list of items, MG drafted the follow-up form. Several drafts were discussed in an
adapted Delphi process to tailor its contents to different settings and make it appropriate for both clinical
use and research (figure 1). >80% of the working group members participated in every discussion round.
Overall the process included four discussion rounds, where all members were invited to comment on the
latest draft by 1) suggesting items to be removed or added and 2) commenting on the specific phrasing
and wording of the included items, the sequence of the questions and the overall structure. The process
involved discussions at BEAT-PCD conferences, telephone and skype calls and email communication.
A main issue raised during discussions was structure. Related to the structure, the discussions focused on
whether there should be two main versions, one for the baseline assessment and one for follow-up visits.
As an alternative, we discussed a form with several distinct modules. This would permit completing all
modules at baseline and during annual reviews and fewer modules during 3-monthly routine follow-up.
The working group took into account the validated PCD quality of life questionnaires to avoid overlaps so
that the instruments can be used together and complement each other [16–19]. After each round, MG
resolved disagreements among participants, contacting them individually if required, and then made the
next draft. Particular consideration was given to comments and suggestions by adult pulmonologists and
experts on specialised topics. When there was no clear decision, different options were included in the
revised draft asking the group to decide. Each decision was taken with agreement of the majority (>80%)
of the participants of each round. Details on specialised topics such as genetics, diagnostic testing, upper
airways and physiotherapy were discussed with the experts before and during the group discussions.
A final group discussion resulted in the development of version 1.0 of FOLLOW-PCD.
Ethics and data agreements
Local collaborators are responsible for obtaining ethics approval and informed consent in their country for
use of FOLLOW-PCD to collect prospective clinical data and use it for research nationally and
internationally.
Results
Standardised PCD follow-up form (FOLLOW-PCD)
We strived for an easy and practical instrument for clinical use, but also considered it important that it is
comprehensive (box 1). The working group unanimously agreed to a modular structure, which permits
different members of the multidisciplinary team (pulmonologists, otolaryngologists, diagnostic experts,
physiotherapists, lung function technicians, etc.) to complete different modules (table 1). After agreeing on
the modular structure, the working group decided to prepare two versions of the modules on patient-reported
outcomes (symptoms and environment-lifestyle). Version A is formatted for completion by the physician
during the clinical visit, similarly to the other modules. Version B collects the same information, but is
formatted as a questionnaire, which can be completed directly by patients. In addition, we created
age-adapted versions for these modules, because some symptoms and relevant exposures vary by age, for
instance questions on active smoking for adults and adolescents versus parental smoking for children. We also
decided to have FOLLOW-PCD available both as paper form and as an electronic database.
Structure and content of FOLLOW-PCD
Version 1.0 of FOLLOW-PCD consists of seven modules (table 1). It is possible to have a more extensive
evaluation at baseline and annual reviews, when all modules are completed and a short documentation at
routine (e.g. 3-monthly) follow-up, where only a few modules are used (box 1). Module 1 must be filled
only at the first visit (at diagnosis or referral from other clinic) and includes demographic information,
extensive diagnostic data, information on unchanging congenital abnormalities (e.g. situs inversus, cardiac
defects) and a baseline medical history. The module can be updated at any time if patients have had
additional diagnostic tests performed.
Modules 2–7 are designed for use at baseline and during routine follow-up visits. These modules include
physical examination of the lungs, heart and upper airways, growth measurements, measurement of lung
function, microbiology and imaging, information on hospitalisations, surgeries, prescribed treatments and
medical history. Table 2 presents the content included in each module. Modules 6 and 7 contain
patient-reported information on clinical symptoms and lifestyle (e.g. exercise and smoking).
For annual reviews, all modules are recommended. For routine 3-monthly follow-up visits, each clinic can
use the modules that fit the local routine practice, using for example module 2 for the examination of
https://doi.org/10.1183/23120541.00237-2019 4
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lungs and heart, parts of modules 4 (growth and lung function, microbiology) and 5 (medication and
physiotherapy) and module 6 administrated as a patient questionnaire or completed by the physician.
Patient questionnaires
For modules 6 and 7 there is the option to complete the physician forms (version A) or the patient
questionnaires (version B), or both and compare them. There are three age-related versions of the
questionnaires: one for adult patients, one for adolescents aged 14–17 years and one for the parents or
caretakers of patients aged <14 years, with different questions on work or school attendance, physical
activity and smoking.
Electronic data entry
In addition to the paper version, the standardised PCD follow-up form is available electronically through
the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University (Nashville,
TN, USA) [20]. Centres using the REDCap platform can enter prospective standardised clinical data that
can be pooled for collaborative studies (box 2). REDCap is secure, widely used in academic research and
allows data entry and extraction in various formats. We designed one central REDCap database, hosted
and managed at ISPM Bern. All collaborators have personal access accounts, which allows access only to
data from their centre. In the electronic version of FOLLOW-PCD, collaborators are invited to enter
BOX 1 FOLLOW-PCD: an instrument for standardised medical record keeping for
patients with primary ciliary dyskinesia (PCD)
FOLLOW-PCD is:
• a standardised instrument for recording information collected during baseline and routine follow-up
visits of patients with PCD
• developed by an interdisciplinary working group of adult and paediatric pulmonologists,
otolaryngologists, physiotherapist and clinical nurse specialists
• a way of recording information on past and current medical history, physical examination, diagnostic
tests and prescribed treatment
• a modular instrument, allowing to document extensive information at the time of diagnosis, and
during annual reviews, and short updates during routine (e.g. 3-monthly) visits
• a flexible tool that can be completed by different healthcare professionals (e.g. pulmonologists
otolaryngologists, physiotherapists, nurses) and patients or caregivers themselves (data on
symptoms, lifestyle and environment)
FOLLOW-PCD will allow the PCD community to:
• collect routine clinical data in a standardised prospective way
• cover most aspects that are relevant for management and care
• compare and pool data between centres for benchmarking and monitoring, compare diagnostic and
prognostic investigations and treatments between centres and countries
• have a real-life representative dataset available for international monitoring and research
• perform high-quality real-time research on clinical questions such as phenotypes, severity and
prognosis, or response to treatments in patients with PCD and to study the factors that influence them
• base clinical decision-making on real-life, contemporaneous and representative data based on large
numbers of patients
TABLE 1 Modules included in the standardised pulmonary ciliary dyskinesia (PCD) follow-up
form (FOLLOW-PCD)
To be completed by clinical
staff
1 Patient information, diagnostic evaluation and baseline medical history
2 Physical examination of lungs and heart
3 Physical examination of upper airways and ears
4 Growth measurements and clinical tests (lung function, imaging,
microbiology)
5 Hospitalisations and treatment (surgeries, medication, physiotherapy)
6 Clinical symptoms (version A)
7 Environment and lifestyle (version A)
To be completed by patients
8 Clinical symptoms (version B)
9 Environment and lifestyle (version B)
https://doi.org/10.1183/23120541.00237-2019 5
PRIMARY CILIARY DYSKINESIA | M. GOUTAKI ET AL.
TABLE 2 Content categories of the standardised pulmonary ciliary dyskinesia (PCD) follow-up form (FOLLOW-PCD version 1.0)
and degree of agreement of the working group members for their inclusion
Module and content category Main included components Degree of group
agreement# %
Module 1
Demographic information Date of birth, sex, ethnicity 98–100
Diagnostic status Current diagnosis and date, other ciliopathies 93–95
Diagnostic tests performed
and results
nNO measurement: date, result, information on equipment and manoeuvre
EM: date, sample quality, EM phenotype and % of affected cilia, ciliary culture
HSVM: date, sample quality, beat frequency, beat pattern, ciliary culture
Genetic analysis: date, technique, genes tested, result, variant nomenclature used
Immunofluorescence: date, absent proteins, positive proteins
95–100
Differential diagnosis Immunodeficiency (dates and results of test performed)
Cystic fibrosis (dates and results of test performed)
83–100
Baseline medical history Detailed history of neonatal period (symptoms, management, gestational age, birth
weight, information on breastfeeding)
Laterality defects (laterality status and cardiovascular malformations, tests and dates of
diagnosis)
Fertility problems (test performed, date and result, number of own children)
Retinitis pigmentosa (date of diagnosis)
Hydrocephalus (test performed, date and result)
Kidney problems (problem description, date of diagnosis)
Gastrointestinal problems (problem description, test performed, date of diagnosis)
Upper and lower respiratory symptoms (overview of selected characteristics from the
past history, e.g. age of symptom onset, bronchiectasis location and age of diagnosis,
pathogens and duration of chronic upper or lower respiratory colonisation, level of
hearing impairment and date of evaluation)
Previous surgical interventions related to PCD
Other PCD-related problems
80–100
Non-PCD-related
comorbidities
Information on atopic diseases, e.g. asthma, hay fever, atopic dermatitis, tests
performed and results, medication allergies
80–93
Family history Consanguinity, PCD in the family, family history of other relevant manifestations 98–100
Module 2
Vital signs Respiratory rate, SpO2 93–95
Clinical examination e.g. signs of dyspnoea, clubbing 95–100
Lung auscultation Pathological sounds and location 93–95
Heart auscultation Description of pathological findings 80–93
Module 3
Examination of the nose Discharge and aspect, mucosa, polyps, other findings 80–95
Examination of the sinuses Facial pain/sensitivity 93–95
Examination of the ears Discharge and aspect, otoscopy, audiometry and tympanometry findings 95–100
Module 4
Growth measurements Height, weight, date of measurement 98–100
Lung function Spirometry (date and several indices)
Plethysmography (date and several indices)
Lung diffusion testing (date and DLCO result)
Inert gas washout measurements (date, type of test, type of gas and concertation,
number of trials, several indices)
Exhaled breath analyses (date and FeNO result)
Information on bronchodilation testing (pre- and post-results)
Information on quality of test performed and references used
93–100
Imaging (date and findings) Chest radiography (date, findings, e.g. atelectasis, infiltrations, bronchial thickening)
Chest CT (date, findings, e.g bronchiectasis, atelectasis, infiltrations, lobar collapse,
mucus plugging, location of bronchiectasis, Brody II score)
Lung MRI (date, findings, e.g bronchiectasis, atelectasis, infiltrations, lobar collapse,
mucus plugging, location of bronchiectasis)
Sinus radiography (date and findings)
Sinus CT (date, findings and location: aplasia, hypoplasia, bone thickening,
Lund–Mackay score)
95–100
Microbiology Date of culture, type of sample, isolated pathogens, antibiotic resistance 95–100
Module 5
Hospitalisations and surgeries Reason for hospitalisation and numbers of hospitalisation days 93–95
Continued
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pseudo-anonymised data and keep personal information (e.g. names, addresses) separately, held locally at
each centre. Data sharing agreements with centres who use the online REDCap platform leave all rights
with data contributors (supplementary material).
Data collected on the REDCap platform can easily be extracted and imported into national registries or
used for local analyses and clinical audits. Centres contributing to the European Reference Network-Lung
PCD registry can easily transfer relevant variables from FOLLOW-PCD to the registry in order to avoid
duplication of data entry efforts [8]. For centres contributing to the international PCD (iPCD) cohort, data
are automatically linked between iPCD and FOLLOW-PCD, allowing the combination of retrospective and
prospective data for certain analyses [21–24].The iPCD cohort aims to use FOLLOW-PCD for all patients
who are in clinical follow-up.
Discussion
This article describes the development and content of a standardised form for collection of clinical data
during routine care of PCD patients. The comprehensive clinical form allows collection of standardised
routine care data to use in clinical decision-making and in local and collaborative research in observational
studies and clinical trials. FOLLOW-PCD has a modular structure to allow flexible use based on the local
practice of each centre. It also contains patient questionnaires focusing on symptoms and lifestyle.
The large and interdisciplinary working group and the transparent and inclusive development process are
major strengths of this project. Experts in the field of PCD diagnosis, management and research joined
forces to develop an instrument, which can be used in clinical practice and for research. We took into
consideration feedback of patient representatives as well as needs of different clinical settings, e.g.
paediatric and adult, larger and smaller centres. The forms allow the collection of patient-reported data on
TABLE 2 Continued
Module and content category Main included components Degree of group
agreement# %
Medication Antibiotics for acute infection (diagnosis, antibiotic class, route, length of treatment)
Prophylactic antibiotics (antibiotic class, route, dosage, start date)
Oxygen supplementation/ventilation (type and frequency of ventilation)
Other prescribed medication (e.g. bronchodilators, corticosteroids)
Relevant vaccinations (type and date of flu and pneumococcal vaccine)
93–100
Physiotherapy Upper airways management (type and frequency of intervention)
Lower airways management (type and frequency of interventions performed routinely
and during exacerbations, nebulisation of lower airways, routine visits to professional
physiotherapist)
Compliance to treatment
Exercise recommendations
80–95
Module 6
Symptoms from the upper
airways and ears
Description, severity and periodicity:
chronic nose symptoms
headaches
ear symptoms
snoring
93–100
Symptoms from the lower
airway
Description, severity and periodicity:
cough
sputum production
wheezing
shortness of breath
chest pain
95–100
General symptoms e.g. fever 93–95
Module 7
Daily activities Information on working status, days off work/school because of PCD, sports 80–95
Smoking Active, passive, type and frequency 93–95
Nutrition Appetite, dietary supplements 85–93
Environment Information on neighbourhood traffic, condensation/mould in the house 80–85
nNO: nasal nitric oxide; EM: electron microscopy; HSVM: high-speed video microscopy; SpO2: oxygen saturation measured by pulse oximetry;
DLCO: diffusing capacity of the lung for carbon monoxide; FeNO: exhaled nitric oxide fraction; CT: computed tomography; MRI: magnetic
resonance imaging. #: range of degree of agreement for the different components of the content category.
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symptoms and on lifestyle. This type of data has not been collected before, and could contribute to
understand long-term prognosis and some of the mechanisms behind the clinical variability of PCD. The
form is extensive, but has a modular structure allowing centres to choose which modules they want to use
and by whom they should be filled in (e.g. physicians, physiotherapists, patients). Implementation in
clinical practice might be a lengthy process, particularly the integration of the form into electronic patient
record system. In the meantime, the REDCap database allows electronic data entry in real-time.
Data collected using FOLLOW-PCD is available in real-time for national and international monitoring and
research. Collaborating centres can easily extract their data and analyse them locally to observe trends (e.g.
on bacterial resistance) or to audit their practice (e.g. on prescribed medication or physiotherapy). Clinical
teams can then adjust local practice based on their results. It will also allow comparison of care practice
between centres at a national or European level for clinical benchmarking of centres. Standardised data can
be used for local and collaborative research. The level of detail depends on how extensively each centre uses
the form, but ideally, there will be no need for researchers to go back to patient charts to retrospectively
retrieve data. In addition, data include patient-reported information on symptoms and lifestyle, which
have not been collected in a standardised way in the past. Future analyses can compare different PCD
phenotypes, age-related variability and the factors that influence prognosis. In addition, standardised
routine observational data will improve the identification of eligible patients for collaborative clinical trials.
The value of standardised data collection for routine clinical data is not a new concept. For many years,
clinicians have made efforts to improve their local patient forms and electronic systems to improve care of
patients with chronic diseases [25]. For rare diseases, this is particularly important [26, 27]. CF is a
characteristic example of a rare disease that has benefited greatly from large long-standing registries
[28–30]. However, registries usually collect a minimal dataset and need to be completed in addition to
regular clinical forms increasing the workload of healthcare professional. FOLLOW-PCD allows to record
all data directly during routine clinical assessments in a standardised way. It is not yet another
international registry, but an instrument for the documentation of patient visits in hospital records, and
ideally will soon be integrated into the clinic information systems and replace the currently available data
entry fields, which vary significantly between centres. Its widespread use in the future will be crucial for
improving research and care for patients with PCD.
Next steps
The original versions of the follow-up form and questionnaires are in English. The patient questionnaires
are currently being translated into German and French. Translations into Norwegian, Danish, Dutch,
Turkish, Greek, Spanish and Arabic are planned. For each language, two native speakers with proficiency
in English and experience in PCD or patient-reported symptoms translate the questionnaire
independently. A back-translation ensures that each language version remains true to the original. The
translation process is organised by the managing team at ISPM Bern. The questionnaires will be validated
in prospective collaborative studies.
BOX 2 FOLLOW-PCD: how to contribute
How to participate in the pilot phase
Centres that wish to participate to the project and pilot the form should contact the study team
(pcd@ispm.unibe.ch). We will provide advice where additional ethical approval is needed. Centres will be
asked to sign a data agreement that leaves them all rights to their data. The centres will then receive a
password to access the online software REDCap and they will be able to enter their data directly. We
will provide technical support for the whole process
How to access data
Centres using the electronic form on REDCap will have constant access to their datasets and can export
them directly in various formats for local analyses or transfer to national registries. We have developed
detailed instructions to simplify the data extraction procedure
How to translate the questionnaire
Centres that wish to use the patient questionnaire in another language should contact the study team
who will assist in organising the standardised translation process
Researchers who want to use the collected data can propose a topic and a concept sheet describing the
planned analyses and publication. Concept sheets have to be approved by centres who want to
contribute data to the proposed analysis. Centres who want to participate sign a publication agreement.
The study team will then prepare a dataset for the proposed analysis and will work closely with the lead
researchers, offering methodological input and support
For further details, contact pcd@ispm.unibe.ch
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The clinic forms will be piloted in several paediatric and adult PCD outpatient clinics, to test the
instruments in real-life conditions and identify items that need to be added or eliminated or if variables must
be recoded or further clarified. We plan to pilot the form for a period of 6–12 months in interested centres
including different countries and centres of various sizes to make sure it fits different settings (box 2). Our
aim is to enrol ∼100–200 patients from five or more countries. We will invite a broad spectrum of centres to
make sure we can pilot all aspects of the instrument with sufficient numbers of patients. This includes
paediatric and adult centres, specialised pulmonology and ear, nose and throat clinics and centres where
certain forms are completed by specialised team members (e.g. physiotherapists) or by patients instead of
physicians. We will analyse the data collected during the pilot phase together to evaluate rate of completion
of each variable. We will collect comments by the clinical teams of participating centres using a pre-designed
form and by participating patients, through the patient questionnaire and the PCD patient organisations.
The comments will aim to identify missing items and items that need clarification or recoding. In addition,
we will ask if there are redundant items that are not clinically useful or take too much time to complete.
Based on the results from the piloting phase, we will suggest changes to the form and use further rounds of
the Delphi process, to develop a refined form (FOLLOW-PCD version 2.0).
Conclusion
In a large, international and multidisciplinary group of PCD experts, we developed FOLLOW-PCD, a
standardised clinical PCD form and patient questionnaire. The form will be adapted after piloting in
different settings and we encourage and facilitate the translation of the questionnaires into multiple
languages. FOLLOW-PCD will facilitate quality research based on prospective standardised data from
routine care, which can be pooled between centres, to provide first-line and real-time evidence for clinical
decision-making.
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